What is RLF-100™’s mode-of-action? RLF-100TM is a synthetic Vasoactive Intestinal Peptide (VIP) that has a multimodal mechanism of action. It binds to Type 2 alveolar cells (found in the lungs), resulting in a significant modulation of the immune cell response (macrophages, CD4-T cells and tolerogenic dendritic cells) mediated by activation of the VPAC1 and VPAc2 receptors. RLF-100TM thus plays an anti-inflammatory and immunomodulatory role vis-à-vis the immune cells; {VPAC1} has vasodilatory and inotropic effects through the vascular system;{VPAC2} and helps to maintain the bronchial system by upregulating the production of surfactant in the lungs, preventing cell death.
Market Data 
Markets 
AI
